Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ACHE | P22303 | 8/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948745 | 0.88 | GABBR2 (0.37) | TLR2LMNAACHEEPHX1MMP2 | |
| SCHEMBL2952566 | 0.87 | TLR2 (0.36) | TLR2LMNAACHEEPHX1MMP2 | |
| SCHEMBL1885982 | 0.82 | ACHE (0.33) | TLR2LMNAACHEEPHX1MMP2 | |
| SCHEMBL1884602 | 0.80 | LMNA (0.34) | LMNA | |
| SCHEMBL1888061 | 0.80 | LPAR2 (0.40) | LMNAACHEEPHX1MMP2ALOX15 | |
| SCHEMBL1887582 | 0.80 | MEN1 (0.33) | LMNA | |
| SCHEMBL2948184 | 0.79 | CTSK (0.35) | — | |
| SCHEMBL1892642 | 0.79 | ACHE (0.44) | TLR2ACHEEPHX1MMP2LPAR1 | |
| SCHEMBL1887525 | 0.78 | LMNA (0.35) | LMNA | |
| SCHEMBL18848221 | 0.78 | ALDH1A1 (0.36) | LMNAACHEEPHX1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935686-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | XENOPORT, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | APEH, AASDHPPT, AGPS | TLR2 3565/4885LMNA 3723/4885ACHE 178/4885 |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | APEH, AASDHPPT, AGPS | TLR2 3565/4885LMNA 3723/4885ACHE 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.